T0	Outcomes 382 426	safety, tolerability, and antiviral activity
T1	Outcomes 1554 1596	frequency of infection and viral shedding;
T2	Outcomes 1742 1750	infected
T3	Outcomes 2029 2061	viral titer area under the curve
T4	Outcomes 2293 2332	median (IQR) duration of viral shedding
T5	Outcomes 2443 2457	symptom scores
T6	Outcomes 2530 2568	nasal proinflammatory cytokine levels.
T7	Outcomes 2579 2602	mild to moderate nausea